# Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

> **NCT05142189** · PHASE1 · RECRUITING · sponsor: **BioNTech SE** · enrollment: 320 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** BNT116
- **BIOLOGICAL:** Cemiplimab
- **DRUG:** Docetaxel
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **BIOLOGICAL:** BNT316
- **BIOLOGICAL:** anti-B7-H3 antibody conjugated to topoisomerase I inhibitor
- **BIOLOGICAL:** anti-HER3 antibody conjugated to topoisomerase I inhibitor
- **BIOLOGICAL:** Bispecific antibody for PD-L1 and VEGF-A
- **BIOLOGICAL:** Osimertinib
- **BIOLOGICAL:** ALK-inhibitor or RET-inhibitor

## Key facts

- **NCT ID:** NCT05142189
- **Lead sponsor:** BioNTech SE
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-17
- **Primary completion:** 2030-02
- **Final completion:** 2031-11
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05142189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05142189, "Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05142189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*